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Introduction 
Over the last three decades, interest in the field of gene therapy seems to have fluctuated between 
hot and cold. Encouraging pre-clinical and clinical data has demonstrated the potential of genetic 
therapies and yet setbacks in clinical trials have cast doubts in some minds over the clinical future of 
gene therapy  [1-3]. In the last two years, a number of studies have demonstrated therapeutic benefits 
in clinical trials aimed towards specific monogenetic disorders  [4-6], and this has brought renewed 
optimism to the field. 
Loosely defined, gene therapy is the process of treating a particular disease through the introduction 
of genetic material in order to elicit a therapeutic benefit. While the genetic mutations underlying 
various diseases are well understood, delivering a corrective gene to the diseased organs/tissues 
remains a formidable challenge. Ultimately, the inability to successfully and specifically target enough 
of the correct cell types will limit the prospects of a beneficial outcome. Therefore, gene therapy 
strategies remain limited by the chosen method of gene delivery system. 
While several methods of gene transfer have been used in genetic therapies, the process of virus-
mediated gene transfer has been far and away the most popular within the gene therapy 
community  [7]. As viruses can be manipulated with relative ease and through evolution have attained 
the ability to efficiently deliver their genomes to the nucleus of many different cell types and organs, 
they make good gene transfer vectors. For individual therapies the requirements of a viral vector differ 
according to the nature of the disease. While some therapies require long-term gene transfer, others 
require short-term or even regulated gene delivery. In some cases widespread gene transfer is a 
requirement, whereas localized gene transfer is preferred in others. Furthermore, gene packaging 
capacity and safety issues are also considerations when choosing which viral vector might be suitable 
for a given therapy. Although many different viruses have been modified to serve as gene transfer 
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vectors, it is not always clear which is the best at meeting the requirements of a particular approach to 
treat a given disease.  
This special issue introduces recent advances in the development of commonly used and lesser 
known viral vector systems. It demonstrates that there are multiple options open to researchers wanting 
to use viral vectors to treat specific diseases. Finally, it discusses some of the safety and toxicity 
concerns that face the use of viral vectors. 
Commonly used viral vectors 
In gene therapy clinical trials the most commonly used gene delivery systems have been based on 
adenovirus (Ad), retrovirus, poxvirus, adeno-associated virus (AAV) and herpes simplex virus (HSV), 
which were cumulatively used in more than 66% of all clinical trials to date   [7]. Initially, gene 
delivery systems were developed from these viruses since they are easily manipulated in vitro and have 
been studied in great detail. These viral vectors have a wide range of attributes that determine their 
suitability for different therapeutic applications.  
Although Ad vectors have been widely used in a vast number of different pre-clinical applications, 
in the clinic they have mainly been considered for use in applications such as cancer gene therapies or 
vaccination that require short-term gene transfer to specific cell types and/or organs (For detailed Ad 
review see  [8]). The lack of Ad integration machinery and host immune responses limits their use for 
long-term therapies, while the relative toxicity and high levels of human exposure make it undesirable 
for some therapies. In this issue Wong et al. discuss some of the developments made with oncolytic Ad 
vectors while Seto et al. discuss the use of bioinformatics-based approaches to identify and design 
novel Ad vectors. 
Retrovirus vectors based on the murine leukemia oncoretrovirus (MLV) were the first to be used in 
gene marking and clinical trials in humans  [9,10]. Retroviral vectors are able to efficiently infect 
dividing cells and stably integrate their genome to enable long term gene expression and this makes 
them good candidates for use in a number of therapies, including hematopoietic gene therapy. 
Unfortunately, tumorgenesis caused by integration of MLV sequences close to oncogenes in clinical 
trials has shown the limitations of such vectors  [11], although newer generation retroviruses based on 
lentiviruses (including HIV) and foamy viruses have shown more favorable attributes, including the 
ability to infect non-dividing cells. In this issue Castellani and Conese introduce lentivirus vectors, and 
introduce their use in the development of therapies aimed at treating cystic fibrosis.  
Poxviruses and in particular vaccinia virus have been widely used as gene therapy vectors, primarily 
as agents for vaccination (For detailed review see  [12]). Through its use as a vaccine to eradicate 
smallpox, vaccinia has a well defined history of safe use as a vaccine vector in humans, and as such 
poxviruses have been developed for other genetic therapies that use a vaccination approach to 
treatment. More recently, poxviruses have also successfully been adapted for use as oncolytic vectors 
that are able to selectively kill tumor cells, and in this issue Wong et al. will discuss some of the 
developments made with oncolytic poxvirus vectors. 
AAV is considered to be the safest viral vector system since it is based on a non-pathogenic human 
virus that can only replicate in the presence of a helper virus co-infection. For this reason, AAV is 
quickly becoming the viral vector of choice in clinical trials and particularly those which require long-Viruses 2010, 2                                       
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term correction or enhancement of a genetic defect. While AAV has a good safety profile and is able to 
facilitate long-term gene expression to several organs, it is limited by a number of factors. The small 
genome of AAV limits the size of potential therapeutic genes that can be packaged, while there is a 
clear inability to efficiently infect certain cell types (such as hematopoietic stem cells) that are 
considered essential targets for a number of genetic therapies. For those of you with a desire to learn 
more about AAV there are a number of reviews that nicely introduce its advantages and disadvantages 
as a gene therapy vector  [13,14]. Additionally, in this issue Müther et al. introduce a number of 
systems that utilize the integration machinery of AAV in hybrid viral vectors that target somatic 
integration. 
As one of the largest human viruses, HSV is one of the most complex in terms of replication cycle 
and pathogenesis. Nevertheless, HSV has successfully been developed into a viral vector system that is 
primarily used in neurological therapies due to its natural neurotropism (For detailed review see  [15]). 
While promising results have been seen using HSV vectors to treat neurodegenerative disorders or 
glioblastoma, the inherent toxicity of HSV has limited its use further. In this issue, de Silva & Bowers 
introduce a safer form of HSV amplicon vectors that express no viral genes. 
New types of viral vectors 
In addition to the more commonly used viral vectors many other viral families have been used as 
gene transfer vectors. While most of them have not been used in clinical studies, there is an abundance 
of developmental and pre-clinical data demonstrating the various merits of these systems. Since the 
number of viral vector systems based on different viruses is vast, I have selected some interesting and 
novel systems to introduce in this special issue. 
Several members of the alphavirus genus from the togoviridae family including the Semliki Forest 
virus (SFV), Sindbis virus (SIN) and Venezuelan Equine Encephalitis (VEE) have been developed into 
gene expression vectors in recent years. While their use has not been widespread and problems related 
to virus-induced toxicity have been seen, their prominent neurotropism has made them attractive for 
use in certain CNS-related gene therapies. Kenneth Lundstrom introduces the development of 
alphaviruses into effective gene transfer vector systems in this issue. 
Instead of optimizing a given virus directly to improve its performance as a viral vector, the process 
of combining elements from different viruses or combining non-viral elements with viral elements to 
improve vector performance has gained a lot interest. These novel hybrid vector systems have shown a 
number of favorable attributes that make them attractive candidates for a number of gene therapies. In 
this issue, Müther et al. introduce a number of viral hybrid vector systems that have been developed 
for facilitating somatic integration of therapeutic genes. 
As an alternative to switching viral families or genus in order to change the properties of viral 
vectors, several groups have proposed the encapsidation of viral particles with polymers that can serve 
a number of functions  [16]. The primary function of the coat is to hide the virus from the host immune 
system upon in vivo administration, which in turn prevents degradation, increases vector circulation 
time and subsequently tissue transduction. Another function of polymer encapsidation could be to re-
target a virus by first blanketing the particle to ablate its native tropism and then re-targeting the virus 
by conjugating targeting ligands directly to the polymer. In this issue Wonganan & Croyle illustrate Viruses 2010, 2                                       
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the potential of such an approach, and introduce the use of poly(ethylene glycol) (PEG) as a virus 
encapsidation agent and describe the properties of PEGylated viruses in small and large animal 
models. 
Disease-based choice of viral vectors 
The decision which viral vector to use for a given disease poses several problems to the gene 
threrapy researcher. Apart from the obvious need to transduce a particular cell type or organ, the route 
of administration, the total dose needed, and the potential toxicity of a viral vector must be taken into 
consideration. For some diseases, localized delivery to a specific organ is required whereas other 
diseases require body-wide gene delivery to multiple organs.  
Irrespective of whether the aim is to treat a disease/disorder that manifests locally, such as 
Huntington’s disease, or a disease/disorder that manifests throughout the body, such as muscular 
dystrophy, researchers face a series of challenges. For different diseases/disorders the challenges vary 
and multiple different methods of gene transfer could be viable options for treatment. In this issue, 
from Williams et al., and Castellani & Conese illustrate the various challenges one might have to face 
in deciding an approach to treat a particular disease/disorder. Williams et al. discuss the problems 
associated with trying to treat various forms of cardiovascular disease through gene therapy based 
approaches, while Castellani & Conese discuss the use of one particular vector type (lentiviral vectors) 
for the treatment of the monogeneic disorder cystic fibrosis. 
Safety concerns of viral vectors 
With few exceptions, the wild-type forms of the many viruses used to generate viral vector systems 
are pathogenic agents that have their own inherent safety risks. Despite efforts to minimize the 
potential risks of individual viruses through genomic deletion, insertion or direct modification, it is not 
always possible to make a virus ‘safe’ without seriously affecting its ability to function as a useful viral 
vector. Therefore, it is extremely important to know the potential risks of a particular vector before 
using it, and to weigh the pros and cons between potential alternatives.  
One of the main concerns following virus administration in a clinical setting is the rapid initiation of 
host responses to the vector immediately after delivery. Irrespective of whether a patient has had prior 
exposure to the virus being used as a vector, a number of native pathogen recognition systems exist in 
humans that can initiate a host immune/inflammatory response to the vector. This host response can be 
deleterious in a number of ways as it might hinder the effectiveness of the therapy  [17] or, more 
importantly, the health of the patient  [18]. To address the issue of host responses against the vector 
from a virological perspective, Dmitry Shayakhmetov discusses innate immune responses towards non-
enveloped viruses, and how they impact the effectiveness of vectors used for gene delivery.  
Summary 
Aside from their ability to cause disease in many species spanning, amongst others, reptiles, 
amphibians, fish, birds, and mammals, viruses offer the scientific researcher a wonderful series of tools 
for developing an understanding of disease and cell biology. Furthermore, they offer us methods of Viruses 2010, 2                                       
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gene transfer that have the potential to be used beneficially in the treatment of many human diseases. It 
is my hope that this special issue introduces some of the more widely used viral vectors being used in 
gene therapy research, while also demonstrating that there are new vector systems available. Without 
the continuous development of improved and safer viral vectors, the advancement of genetic therapies 
will not continue. 
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